[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636820":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":11,"centralContacts":27,"locations":33,"responsibleParty":47,"collaborators":11,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":51,"sex":57,"minAge":58,"maxAge":11,"enrollmentInfo":59,"targetDuration":11,"studyType":62,"phases":63,"briefSummary":66,"conditions":67,"keywords":72,"overallStatus":36,"whyStopped":11,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"COMPASS Pathways","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"1 mg COMP360 psilocybin","ACTIVE_COMPARATOR",null,[13],"Drug: COMP360 psilocybin",{"label":15,"type":16,"description":11,"interventionNames":17},"10 mg COMP360 psilocybin","EXPERIMENTAL",[13],{"label":19,"type":16,"description":11,"interventionNames":20},"25 mg COMP360 psilocybin",[13],[22],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":11},"DRUG","COMP360 psilocybin","COMP360 psilocybin administered with monitoring and support",[9,15,19],[28],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},"Redefine Study Call Center","CONTACT","202-459-9258","TheRedefineStudy@compasspathways.com",[34],{"facility":35,"status":36,"city":37,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":11},"NY","RECRUITING","New York","10025","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-74.00597,40.71427,{"lat":45,"lon":44},{"type":48,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100636820","phase-2-redefine-study-a-study-evaluating-the-efficacy-safety-and-tolerability-of-comp360-in-participants-with-post-traumatic-stress-disorder-100636820",false,"NCT07570654","Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder","A Phase 2b\u002F3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder","Redefine","Inclusion Criteria:\n\n* 18 years or older\n* Diagnosed with PTSD at least 6 months ago\n\nExclusion Criteria:\n\n\\- Diagnosed with certain psychiatric conditions such as bipolar disorder, schizophrenia, OCD, anorexia, or other conditions","ALL","18 Years",{"count":60,"type":61},300,"ESTIMATED","INTERVENTIONAL",[64,65],"PHASE2","PHASE3","The Redefine Study (COMP202) is testing COMP360 to see if it may reduce post-traumatic stress disorder (PTSD) symptoms when administered alongside monitoring and support from a trained study team. COMP360 is a lab-made form of the naturally occurring chemical compound psilocybin.",[68,69,70,71],"PTSD - Post Traumatic Stress Disorder","PTSD","PTSD Symptoms","PTSD, Post Traumatic Stress Disorder",[73,74,55,69,75],"COMP360","psilocybin","trauma","2026-08-14",{"date":78,"type":79},"2026-08-18","ACTUAL",{"date":81,"type":61},"2026-09",{"date":83,"type":61},"2029-09",{"name":5,"class":6},1]